South Africa has resumed use of Johnson & Johnson’s single-dose COVID-19 vaccine, ending a temporary pause that followed reports of extremely rare but severe blood clotting in patients. Fewer than one in a million recipients of Johnson & Johnson’s shot developed the disorder.

Here in the United States, a panel of vaccine experts meets today to discuss whether to recommend resuming use of the shots.

Daily coronavirus infections continue to hold steady at a relatively high level in the U.S., with 67,000 new infections and more than 900 deaths reported Thursday.